Instrumento Inactivo

Otros idiomas Beigene Ltd Hong Kong S.E.

Acciones

Precio de cierre Hong Kong S.E. Otros sitios de cotización
- ^HKD	-

23/04	Actualización del sector: Las acciones del sector sanitario suben en las operaciones de la tarde	MT
23/04	BeiGene dice que el tislelizumab obtiene la aprobación de la Comisión Europea para tratar el cáncer de pulmón no microcítico; las acciones suben	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

BeiGene : Financial Information - Form 8-K	26/04
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report	26/04
Globaler Onkologie-Innovator BeiGene präsentiert auf der ASCO-Jahrestagung 2024 neue Daten aus dem gesamten Portfolio für Hämatologie und solide Tumore	25/04
BeiGene, innovateur mondial en oncologie, présente de nouvelles données sur l’ensemble de son portefeuille en hématologie et en tumeurs solides lors de la réunion annuelle de l’ASCO 2024	25/04
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting	24/04
BeiGene erhält von der EU-Kommission die Zulassung für Tislelizumab zur Behandlung von nicht kleinzelligem Lungenkrebs	24/04
BeiGene reçoit l’approbation de la Commission européenne pour le tislelizumab dans le traitement du cancer du poumon non à petites cellules	24/04
Sector Update: Health Care Stocks Rise in Afternoon Trading	23/04
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	23/04
BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment	23/04
Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	23/04
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer	23/04
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	23/04
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	23/04
BeiGene to Award Shares Worth $15 Million to 11 Directors	17/04
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	11/04
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	11/04
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates	10/04
Beigene Shrinks Loss by 56% in 2023	29/03
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading	22/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Beigene Ltd Hong Kong S.E.

Acciones

Otros idiomas

Filtros